CERRITOS, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that senior management will participate at the following investor conferences:
Cowen 43rd Annual Healthcare Conference
Date: March 7th, 2023
Presentation: 2:50pm Eastern Time
TOI Participant: Daniel Virnich, M.D., MBA, President
Location: Boston, Massachusetts
Oppenheimer 33rd Annual Healthcare Conference
Date: March 13th, 2023
Presentation: 10:00am Eastern Time
TOI Participant: Brad Hively, Chief Executive Officer
Location: Virtual
Jefferies Value-Based Healthcare Summit
Date: March 13th, 2023
Presentation: 1:15pm Eastern Time
TOI Participant: Brad Hively, Chief Executive Officer
Location: Miami, Florida
Interested investors and other parties may listen to simultaneous webcasts of the presentations by logging onto the Investor Relations section of the Company’s website at https://investors.theoncologyinstitute.com/. The online replay will be available for a limited time shortly following the call.
About The Oncology Institute, Inc.
Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.7 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 90+ employed clinicians and more than 700 teammates in over 50 clinic locations and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.
Contacts
Media
The Oncology Institute
Julie Korinke
This email address is being protected from spambots. You need JavaScript enabled to view it.
(562) 735-3226 x 88806
Investors
Solebury Strategic Communications
Maria Lycouris
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$3.73 |
Daily Change: | 0.06 1.63 |
Daily Volume: | 1,570,890 |
Market Cap: | US$342.820M |
June 30, 2025 May 14, 2025 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load